0001209191-23-048258.txt : 20230905
0001209191-23-048258.hdr.sgml : 20230905
20230905201539
ACCESSION NUMBER: 0001209191-23-048258
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230905
FILED AS OF DATE: 20230905
DATE AS OF CHANGE: 20230905
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Cline Christopher R.
CENTRAL INDEX KEY: 0001943192
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36257
FILM NUMBER: 231237558
MAIL ADDRESS:
STREET 1: C/O TRAVERE THERAPEUTICS, INC.
STREET 2: 3611 VALLEY CENTRE DRIVE, STE 300
CITY: SAN DIEGO
STATE: CA
ZIP: 92130
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Travere Therapeutics, Inc.
CENTRAL INDEX KEY: 0001438533
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 262383102
STATE OF INCORPORATION: CA
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 3611 VALLEY CENTRE DR
STREET 2: SUITE 300
CITY: SAN DIEGO
STATE: CA
ZIP: 92130
BUSINESS PHONE: 888-969-7879
MAIL ADDRESS:
STREET 1: 3611 VALLEY CENTRE DR
STREET 2: SUITE 300
CITY: SAN DIEGO
STATE: CA
ZIP: 92130
FORMER COMPANY:
FORMER CONFORMED NAME: Retrophin, Inc.
DATE OF NAME CHANGE: 20130220
FORMER COMPANY:
FORMER CONFORMED NAME: Desert Gateway, Inc.
DATE OF NAME CHANGE: 20080625
4
1
doc4.xml
FORM 4 SUBMISSION
X0508
4
2023-09-05
0
0001438533
Travere Therapeutics, Inc.
TVTX
0001943192
Cline Christopher R.
C/O TRAVERE THERAPEUTICS, INC.
3611 VALLEY CENTRE DRIVE, STE 300
SAN DIEGO
CA
92130
0
1
0
0
Chief Financial Officer
0
Common Stock
2023-09-05
4
S
0
457
14.7102
D
50574
D
Represents the number of shares required to be sold by the Reporting Person to cover the tax withholding obligation in connection with the settlement of vested restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the Reporting Person to fund this tax withholding obligation by completing a "sell to cover" transaction with a brokerage firm designated by the Issuer. This sale does not represent a discretionary trade by the Reporting Person.
/s/ Elizabeth E. Reed, Attorney-in-Fact
2023-09-05